Announced Tue, 27 Oct, 2026 · 20:38 IST
Q2 FY27 revenue rises 13% from Q1; operating EBITDA margin improves to 18%
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Q2 FY27 revenue was Rs 833 crore, up 13% from Q1 but down 9% year on year. Operating EBITDA was Rs 147 crore and margin rose 6 percentage points to 18%. Reported profit after tax was Rs 32 crore versus a Rs 9 crore loss in Q1. H1 revenue fell 12% and margin dropped to 15 percent from 23 percent. Lower Zoetis revenue and currency hedge losses hurt performance. Syngene signed its first Bayview biologics manufacturing agreement.
Likely market impact
Recovery and new biologics work support sentiment, but weaker sales, margins and the chief financial officer's planned exit may limit near-term gains.